[A23-08] Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2023
Project no.:
A23-08
Commission:
Commission awarded on 01.02.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Result of dossier assessment:
- Patients who have received 1 prior trastuzumab-based regimen in first-line therapy: added benefit not proven
- Patients who have received at least 2 prior regimens, including trastuzumab: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-81 | Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-80 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-07 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-115 | Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |